<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644059</url>
  </required_header>
  <id_info>
    <org_study_id>V70P5</org_study_id>
    <secondary_id>Eudract number 2007-003786-41</secondary_id>
    <nct_id>NCT00644059</nct_id>
    <nct_alias>NCT01015885</nct_alias>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to &lt;72 Months) Versus Control Vaccines</brief_title>
  <official_title>A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to &lt;72 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5
      mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza
      and non-adjuvanted influenza control vaccines in subjects 6 to &lt;72 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects (Unprimed) 6 to &lt;36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control.</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Safety was assessed in terms of number of subjects experiencing each of the local and systemic reactions within 7-days after any vaccination for all seasons, comparison of adjuvanted Trivalent influenza vaccine (aTIV) and flu vaccine control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects (Unprimed) Aged 6 to &lt;36 Months With Virus-Confirmed Influenza, Comparison of aTIV and Non-flu Vaccine Control (Men C/TBE Vaccine)</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>Virus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in 6 to &lt;36 month unprimed subjects for Absolute Efficacy. This primary endpoint is only for homologous strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (Unprimed) of 6 to &lt;72 Months Age With Local and Systemic Reactions After Any Vaccination</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>Safety was assessed as the number of subjects aged 6 to &lt;72 months who reported solicited local or systemic adverse events after any vaccination with TIV-adj for all seasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (Unprimed) With Unsolicited Adverse Events Reported After Any Vaccination</measure>
    <time_frame>Study day 1 to Study day 181</time_frame>
    <description>Number of subjects aged 6 to &lt;36 months and in the overall age cohort (unprimed children aged 6 to &lt;72 months) experiencing each of the unsolicited adverse events (AEs) throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (Unprimed) Aged 6 to &lt;72 Months With Virus-Confirmed Influenza, Comparison of aTIV to Non-flu Vaccine Control and Flu-vaccine Control (Matched Strains)</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>Virus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in subjects aged 6 to &lt;72 months (unprimed) for Absolute Efficacy.
For Relative efficacy, the comparison was made between adjuvanted influenza vaccine (TIV-adj) and flu vaccine control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (Unprimed) Aged 6 to &lt;72 Months With Virus-Confirmed Influenza, Comparison of aTIV to Non-flu Vaccine Control and Flu Vaccine Control (Any Strains).</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>Virus-confirmed influenza illnesses (regardless of antigenic match to those contained in the vaccine) were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in subjects aged 6 to &lt;72 months (unprimed) for Absolute Efficacy.
For Relative efficacy, the comparison was made between adjuvanted influenza vaccine (TIV-adj) and flu vaccine control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (Unprimed) With Influenza Like Illnesses (ILIs) in the 6 to &lt;72 Months Age Cohort for Combined Seasons 2007/08 and 2008/09</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine in 6 to &lt;72 month old subjects for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Influenza Like Illnesses (ILIs) in the 6 to &lt;36 Months and in Overall Age Cohort (Unprimed Subjects Aged 6 to &lt;72 Months) for Combined Seasons 2007/08 and 2008/09</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of Days of Usual Activity (Job, School, Day Care, Household/Family/Community Activities) Due to Influenza Like Illness (ILI) in Subjects in Aged 6 to &lt;72 and 6 to &lt;36 Months and in Direct Caregivers Living in the Household.</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Influenza Like Illness for Combined Seasons 2007/08 and 2008/09.</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
    <description>The number of events of Influenza like Illness reported by subjects aged 6 to &lt;72 months was assessed for combined seasons 2007/08 and 2008/09</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMRs, in Unprimed Subjects Aged 6 to &lt;36 Months or Season 2008/09 (Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50 and 181</time_frame>
    <description>The immunogenicity was assessed in terms of Geometric mean titer ratios (GMRs) of study day 29/study day 1, study day 50/study day 1, study day 181/study day 1 were evaluated.
The criteria for evaluation is GMR &gt;2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of Geometric Mean Titers (GMTs), in Unprimed Subjects Aged 6 to &lt;36 Months for Season 2008/09 (Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50 and 181</time_frame>
    <description>Immunogenicity was analyzed in terms of Geometric Mean Titers (GMTs) as measured by hemagglutination inhibition (HI) assay. For each strain and each vaccine group, least squares GMTs, associated 2-sided 95% confidence interval were determined for all time points.
Superiority analysis: GMT-TIV-adj/GMT-Flu-control &gt;1 should be elicited to show that GMT-TIV-adj is superior to GMT-Flu-control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (95% CI) of Unprimed Subjects Aged 6 to &lt;36 Months With HI Titer ≥1:40 in Season 2008/09 HI Assay(Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50, 181</time_frame>
    <description>Percentage of subjects achieving seroprotection (i.e., with HI titer ≥1:40) at study day 1, study day 29, study day 50 and a study day 181 and associated 95% CI. The lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (95% CI) of Unprimed Subjects Aged 6 to &lt;36 Months With Seroconversion From Baseline, for Season 2008/09 (Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50, 181</time_frame>
    <description>HI assay was used for the analysis. Seroconversion is defined as negative pre-vaccination serum (&lt;10)/ post-vaccination HI titer ≥1:40.
Seroconversion is defined as either pre-vaccination HI titer &lt;10 and a post-vaccination HI titer ≥1:40 or a prevaccination HI titer ≥10 and a minimum four-fold rise in post-vaccination HI antibody titer.
The lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMTs, in Unprimed Subjects Aged 6 to &lt;72 Months for Season 2008/09 (Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50 , 181</time_frame>
    <description>Immunogenicity was analyzed in terms of Geometric Mean Titers (GMTs) as measured by hemagglutination inhibition (HI) assay. For each strain and each vaccine group, least squares GMTs, associated 2-sided 95% confidence interval were determined for all time points Superiority analysis: GMT-TIV-adj/GMT-Flu-control &gt;1 and GMT-TIV-adj/GMT-Non Flu-control &gt;1 should be elicited to show that GMT-TIV-adj is superior to GMT-Flu-control/Non Flu-control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMRs, in Unprimed Subjects Aged 6 to &lt;72 Months for Season 2008/09 (Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50, 181</time_frame>
    <description>Hemagglutination Inhibition (HI) assay was used for the analysis. Geometric mean titer ratios (GMRs) of study day 29/study day 1, study day 50/study day 1, study day 181/study day 1 were evaluated.
The criteria for evaluation is GMR &gt;2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With HI Titers ≥ 1:40 in Unprimed Subjects 6 to &lt;72 Months of Age for Season 2008/09 Homologous and Heterologous Strains</measure>
    <time_frame>On study days 1, 29, 50, 181</time_frame>
    <description>Hemagglutination Inhibition (HI) assay was used for the analysis.
Percentage of subjects achieving seroprotection (i.e., with HI titer ≥1:40) at study day 1, study day 29, study day 50 and a study day 181 and associated 95% Confidence Intervals. The lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Seroconversion and Vaccine Group Differences in Unprimed Subjects 6 to &lt;72 Months of Age for Season 2008/09 (Homologous and Heterologous Strains)</measure>
    <time_frame>On study days 1, 29, 50, 181</time_frame>
    <description>HI assay was used for the analysis. Seroconversion is defined as negative pre-vaccination serum (&lt;10)/ post-vaccination HI titer ≥1:40.
Seroconversion is defined as either pre-vaccination HI titer &lt;10 and a post-vaccination HI titer ≥1:40 or a prevaccination HI titer ≥10 and a minimum 4-fold rise in post-vaccination HI antibody titer. The lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Local and Systemic Reactions for Egg and Cell Derived Inactivated Novel Swine Origin A/H1N1 Subunit Influenza Vaccines After Each Vaccination for All Seasons</measure>
    <time_frame>7 days post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect Protective Effect of Fluad (NH Composition 2007/2008), Compared to Non-flu Control and Flu Control, in Connection to Household-contact Persons Via a Questioning of the Parents About ILI of Persons Living in the Same Household as the Study Child</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of the 2009-2010 H1N1 Swine Pandemic Caused by a Novel Influenza A (H1N1) Virus of Swine Origin in Unprimed Children Aged 6 to &lt;36 and 6 to &lt;72 Months</measure>
    <time_frame>3 weeks after 2nd vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4902</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>TIV-adj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvanted trivalent inactivated subunit influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flu-control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-flu Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted trivalent inactivated subunit influenza vaccine</intervention_name>
    <description>Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.</description>
    <arm_group_label>TIV-adj</arm_group_label>
    <other_name>Fluad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</intervention_name>
    <description>For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.</description>
    <arm_group_label>Flu-control</arm_group_label>
    <other_name>1) Agrippal</other_name>
    <other_name>2) Influsplit SSW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine</intervention_name>
    <description>Meningococcal vaccine: two IM injections
Tick-borne encephalitis vaccine: two IM injections</description>
    <arm_group_label>Non-flu Control</arm_group_label>
    <other_name>1. Menjugate</other_name>
    <other_name>2. Encepur Children</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children whose parents/legal guardians have given written informed consent prior to
             study entry: a) aged 6 to &lt;72 months (Part I and II of the study; influenza seasons
             2007/2008 and 2008/2009) b) aged 6 to &lt;36 months (Part III of the study; influenza
             season 2009/2010)

          -  In good health as determined by: a) medical history, b) physical examination, c)
             clinical judgment of the investigator

        Exclusion criteria:

          -  Administration of licensed vaccines (including H1N1sw vaccines) within 14 days (for
             inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this
             study. Routine vaccines, according to local recommendations, or any other vaccines not
             foreseen in the protocol could be given after the active trial phase (i.e., 21 days
             after last vaccination) has been concluded.

          -  Receipt of another investigational vaccine or any investigational agent within 30 days
             prior to enrollment in the study or before completion of the safety follow-up period
             in another study, whichever is longer, and participation in another clinical trial
             during the present study.

          -  Experience of a severe acute infectious disease in the month prior to study start or
             experience of a mild acute infection disease in the week prior the study start
             (untreated common cold is acceptable). The severity of the infectious disease occurred
             will be based on the investigator's judgment.

          -  Any severe acute respiratory disease and infection requiring systemic antibiotic or
             antiviral therapy ongoing or resolved within 2 days prior to study start.

          -  Experience an axillary temperature equal to or greater than 37.8°C (rectal temperature
             equal to or greater than 38.3°C) within the 2 days before enrollment.

          -  Any serious disease in the opinion of the investigator including, for example: a)
             cancer, b) autoimmune disease (including rheumatoid arthritis under immunosuppressive
             therapy), c) insulin dependent diabetes mellitus, d) chronic pulmonary disease, asthma
             under inhalative therapy only is acceptable, e) acute or progressive hepatic disease,
             f) acute or progressive renal disease.

          -  Known or suspected impairment/alteration of immune function, for example, resulting
             from: a) receipt of immunosuppressive therapy (corticosteroid -except topical or
             inhaled steroids- or cancer chemotherapy), b) receipt of immunostimulants, c) receipt
             of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives
             within the past 90 days and for the full length of the study, d) high risk for
             developing an immunocompromising disease (suspected or known HIV infection or
             HIV-related disease).

          -  Bleeding diathesis.

          -  History of hypersensitivity to any component of the study medication or chemically
             related substances.

          -  History of any anaphylaxis, serious vaccine reactions, or allergy to eggs, egg
             products or any other vaccine component.

          -  Laboratory confirmed influenza disease.

          -  History of neurological disorder or seizures (febrile seizures allowed).

          -  Received any influenza vaccine.

          -  Major surgery planned during the study period.

          -  Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives, e.g., planned travel or relocation of residence
             that would interfere with completion of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vacccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Vantaa Clinic</name>
      <address>
        <city>East Vaanta</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki East Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kotka Clinic</name>
      <address>
        <city>Kotka</city>
        <zip>48600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio Vaccine Clinic</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio Vaccine Research Clinic</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahti vaccine research Clinic</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Vaccine Research Clini</name>
      <address>
        <city>Oulu</city>
        <zip>90200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinajoki Clinic</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vantaa West Vaccine Research Clinic</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Vantaa Clinic</name>
      <address>
        <city>West Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Thilo Heising</name>
      <address>
        <city>Aalen Wasseralfingen</city>
        <zip>73433</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Ursula Hornlein</name>
      <address>
        <city>Berlin</city>
        <zip>10315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Thomas Richter</name>
      <address>
        <city>Berlin</city>
        <zip>10551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dipl med Andreas Muhmer</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Mechthild Vocks-Hauck</name>
      <address>
        <city>Berlin</city>
        <zip>10627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Klaus-Peter Falkowski</name>
      <address>
        <city>Berlin</city>
        <zip>10999</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Eva Brand</name>
      <address>
        <city>Berlin</city>
        <zip>12165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Dorothea Budde</name>
      <address>
        <city>Berlin</city>
        <zip>12209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Cornelia Busse</name>
      <address>
        <city>Berlin</city>
        <zip>12589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dipl. med. F. Temmler / Dipl. med. D. Wenzel</name>
      <address>
        <city>Berlin</city>
        <zip>12619</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Petra van Stiphout</name>
      <address>
        <city>Berlin</city>
        <zip>12679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Luise Schroeter</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Praxis Dr med Dietrich Lasius&quot;</name>
      <address>
        <city>Berlin</city>
        <zip>13439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Petra Sandow</name>
      <address>
        <city>Berlin</city>
        <zip>14052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Norbert Meister</name>
      <address>
        <city>Bindlach</city>
        <zip>95463</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Thomas Tuschen</name>
      <address>
        <city>Binngen Rhein</city>
        <zip>55411</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Elmar Dietmair</name>
      <address>
        <city>Bobingen</city>
        <zip>86399</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Brigitta Becker</name>
      <address>
        <city>Bochum</city>
        <zip>44866</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Karl-Heinz Blattel</name>
      <address>
        <city>Braunfels</city>
        <zip>35619</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Roland Knecht</name>
      <address>
        <city>Bretten</city>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Maria R. Holtorf</name>
      <address>
        <city>Brunsbuettel</city>
        <zip>25541</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Klaus Helm</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Joseph Zakarian</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Hans-Henning Peters</name>
      <address>
        <city>Eschwege</city>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Dirk Straub</name>
      <address>
        <city>Essen</city>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Rainer Haase</name>
      <address>
        <city>Flensburg</city>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Per Gildberg</name>
      <address>
        <city>Flensburg</city>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peaxis Dr H Outzen jun</name>
      <address>
        <city>Flensburg</city>
        <zip>24943</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Lothar MaurerJun</name>
      <address>
        <city>Frankenthal</city>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Walter Otto</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Hans-Joachim Buttner</name>
      <address>
        <city>Gau-Odernheim</city>
        <zip>55239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Christian Kayser</name>
      <address>
        <city>Gehrden</city>
        <zip>30989</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Ute Jessat</name>
      <address>
        <city>Gluecksburg</city>
        <zip>24960</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Dubravka Pock-Lutz</name>
      <address>
        <city>Grevenbroich</city>
        <zip>41515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Malte Klarczyk</name>
      <address>
        <city>Hamburg</city>
        <zip>22089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxid Dr. med. Karl-Heinrich Hansen</name>
      <address>
        <city>Hamburg</city>
        <zip>22147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Anna Halat</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Bernard Nast</name>
      <address>
        <city>Hamburg</city>
        <zip>22307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Jurgen Schwalbe</name>
      <address>
        <city>Hameln</city>
        <zip>31785</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Hans-Heinrich Rohe</name>
      <address>
        <city>Hille</city>
        <zip>32479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Marlies Bolich</name>
      <address>
        <city>Jena</city>
        <zip>97745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Peter Bosch</name>
      <address>
        <city>Karlsruhe-Oberreut</city>
        <zip>76189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Peter Andoko Soemantri</name>
      <address>
        <city>Kleve-Materborn</city>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Michael Muehlschlegel</name>
      <address>
        <city>Lauffen</city>
        <zip>74348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Sibylle Hetzinger</name>
      <address>
        <city>Lobenstein</city>
        <zip>07356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dipl med Dagmar Manegold-Randel</name>
      <address>
        <city>Lohne</city>
        <zip>32584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Renate Lang</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Julika Kelber</name>
      <address>
        <city>Luneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-University</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Uwe Jakob</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Falko Panzer</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Volker Tempel</name>
      <address>
        <city>Marbach a. N.</city>
        <zip>71672</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Herbert Kollaschinski</name>
      <address>
        <city>Marktredwitz</city>
        <zip>95615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Matthias Donner</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Ralph Koellges</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Janina Joiko</name>
      <address>
        <city>Muenchen</city>
        <zip>81369</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Praxis Prof Dr med Stefan Walter Eber&quot;</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Peter Dietl</name>
      <address>
        <city>Munchen</city>
        <zip>81475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Philip Fellner von Feldegg</name>
      <address>
        <city>Munster / NRW</city>
        <zip>48163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dipl Med Ute Macholdt</name>
      <address>
        <city>Neuhaus am Rennweg</city>
        <zip>98724</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Rossius</name>
      <address>
        <city>Neumuenster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Sabine Maruschke</name>
      <address>
        <city>Neumuenster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Drs J und K Kandzora</name>
      <address>
        <city>Neumuenster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. S. Mohns-Petersen</name>
      <address>
        <city>Niebuell</city>
        <zip>25899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Hartmut Scheele</name>
      <address>
        <city>Niedernhausen</city>
        <zip>65527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Stefan Noll</name>
      <address>
        <city>Porta Westfalica</city>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Zlatka Zochev Donkov</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Michael Vomstein</name>
      <address>
        <city>Schwabisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Praxis Dr med Gunther Knapp&quot;</name>
      <address>
        <city>Schwieberdingen</city>
        <zip>71701</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Thomas Morandini</name>
      <address>
        <city>Schönenberg</city>
        <zip>66901</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Ulrich Soergel</name>
      <address>
        <city>Stadthagen</city>
        <zip>31655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Ulrich Pfletschinger</name>
      <address>
        <city>Stuttgart</city>
        <zip>70469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med Manfred Heitz</name>
      <address>
        <city>Stuttgart</city>
        <zip>70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med Heidi B. John-Wagenmann</name>
      <address>
        <city>Stuttgart</city>
        <zip>70619</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Rolf Ebert</name>
      <address>
        <city>Tauberbischofsheim</city>
        <zip>97941</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Karl-Eugen Mai</name>
      <address>
        <city>Tettnang</city>
        <zip>88069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Klaus Kindler</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Ralph Maier</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Ulrich Umpfenbach</name>
      <address>
        <city>Viersen</city>
        <zip>41751</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Volker Kemmerich</name>
      <address>
        <city>Weinstadt</city>
        <zip>71384</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Per Bergmann</name>
      <address>
        <city>Winsen</city>
        <zip>29308</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr med Steffi Bulst</name>
      <address>
        <city>Wurzen</city>
        <zip>04808</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico Mangiagalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011 Oct 13;365(15):1406-16. doi: 10.1056/NEJMoa1010331.</citation>
    <PMID>21995388</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <results_first_submitted>October 6, 2011</results_first_submitted>
  <results_first_submitted_qc>October 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2014</results_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled as follows:
In season 2007/08: 28 active sites in Germany (Excluding Site 023); In season 2008/09: 83 active sites+ 1 coordinating site in Germany, 15 sites in Finland; In season 2009/10: 15 sites in Finland, 2 sites in Italy</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial. The data entered is for the overall study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TIV-adj</title>
          <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
        </group>
        <group group_id="P2">
          <title>Flu-control</title>
          <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
        </group>
        <group group_id="P3">
          <title>Non-flu Control</title>
          <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of Tick-borne encephalitis (TBE) vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2019"/>
                <participants group_id="P2" count="1849"/>
                <participants group_id="P3" count="1034"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1895"/>
                <participants group_id="P2" count="1726"/>
                <participants group_id="P3" count="969"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation/violation</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TIV-adj</title>
          <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
        </group>
        <group group_id="B2">
          <title>Flu-control</title>
          <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
        </group>
        <group group_id="B3">
          <title>Non-flu Control</title>
          <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2019"/>
            <count group_id="B2" value="1849"/>
            <count group_id="B3" value="1034"/>
            <count group_id="B4" value="4902"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="19.8"/>
                    <measurement group_id="B2" value="32.6" spread="20.1"/>
                    <measurement group_id="B3" value="32.2" spread="19.8"/>
                    <measurement group_id="B4" value="32.2" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="962"/>
                    <measurement group_id="B2" value="903"/>
                    <measurement group_id="B3" value="484"/>
                    <measurement group_id="B4" value="2349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1057"/>
                    <measurement group_id="B2" value="946"/>
                    <measurement group_id="B3" value="550"/>
                    <measurement group_id="B4" value="2553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (Unprimed) 6 to &lt;36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control.</title>
        <description>Safety was assessed in terms of number of subjects experiencing each of the local and systemic reactions within 7-days after any vaccination for all seasons, comparison of adjuvanted Trivalent influenza vaccine (aTIV) and flu vaccine control.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The analysis was done on Safety set - All subjects in the exposed population who provided post-baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt;36 months received 0.25 mL of each injection of Adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt;36 months received 0.25 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Unprimed) 6 to &lt;36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control.</title>
          <description>Safety was assessed in terms of number of subjects experiencing each of the local and systemic reactions within 7-days after any vaccination for all seasons, comparison of adjuvanted Trivalent influenza vaccine (aTIV) and flu vaccine control.</description>
          <population>The analysis was done on Safety set - All subjects in the exposed population who provided post-baseline safety data.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1178"/>
                <count group_id="O2" value="1068"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625"/>
                    <measurement group_id="O2" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender. at inj.site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785"/>
                    <measurement group_id="O2" value="694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eat. hab.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                    <measurement group_id="O2" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (38-38.9°C) (N=1177,1068)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (39-39.9°C) (N=1177,1068)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;40.0°C) (N=1177,1068)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analg.Antipyr.Used (N=1176,1068)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects (Unprimed) Aged 6 to &lt;36 Months With Virus-Confirmed Influenza, Comparison of aTIV and Non-flu Vaccine Control (Men C/TBE Vaccine)</title>
        <description>Virus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in 6 to &lt;36 month unprimed subjects for Absolute Efficacy. This primary endpoint is only for homologous strains.</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set (FAS) - All subjects in the enrolled set who received study vaccination and provided at least one evaluable serum sample both before and after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Unprimed) Aged 6 to &lt;36 Months With Virus-Confirmed Influenza, Comparison of aTIV and Non-flu Vaccine Control (Men C/TBE Vaccine)</title>
          <description>Virus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in 6 to &lt;36 month unprimed subjects for Absolute Efficacy. This primary endpoint is only for homologous strains.</description>
          <population>Analysis was done on Full Analysis Set (FAS) - All subjects in the enrolled set who received study vaccination and provided at least one evaluable serum sample both before and after baseline.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Season 2007/2008, Matched strain,N=187,97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Season 2008/2009, Matched strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                    <measurement group_id="O2" value="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute vaccine efficacy (VE) was calculated as (1- the relative risk)100%. Relative Risk for virus-confirmed symptomatic influenza illness in the TIV-adj group vs. the non-flu control group. VE denotes the vaccine efficacy, i.e. 1-Itest/Inon-flu ctrl, where I stands for the population average incidence of influenza.
Absolute efficacy of TIV-adj is at most 40% (i.e. the probability of an influenza in the test group relative to that in the non-flu vaccine group is at least 0.6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>81.36</param_value>
            <ci_percent>97.66</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.24</ci_lower_limit>
            <ci_upper_limit>93.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (Unprimed) of 6 to &lt;72 Months Age With Local and Systemic Reactions After Any Vaccination</title>
        <description>Safety was assessed as the number of subjects aged 6 to &lt;72 months who reported solicited local or systemic adverse events after any vaccination with TIV-adj for all seasons.</description>
        <time_frame>7 days post-vaccination</time_frame>
        <population>The analysis was done on Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>TIV-adj (36 to &lt;72 Months)</title>
            <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu-control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>Flu-control (36 to &lt;72 Months)</title>
            <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O5">
            <title>Non-Flu-control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O6">
            <title>Non-Flu-control (36 to &lt;72 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Unprimed) of 6 to &lt;72 Months Age With Local and Systemic Reactions After Any Vaccination</title>
          <description>Safety was assessed as the number of subjects aged 6 to &lt;72 months who reported solicited local or systemic adverse events after any vaccination with TIV-adj for all seasons.</description>
          <population>The analysis was done on Safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1178"/>
                <count group_id="O2" value="833"/>
                <count group_id="O3" value="1068"/>
                <count group_id="O4" value="778"/>
                <count group_id="O5" value="607"/>
                <count group_id="O6" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625"/>
                    <measurement group_id="O2" value="569"/>
                    <measurement group_id="O3" value="481"/>
                    <measurement group_id="O4" value="466"/>
                    <measurement group_id="O5" value="315"/>
                    <measurement group_id="O6" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site ecchymosis(N=1178,833,1068,777,607,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site erythema(N=1178,833,1068,777,607,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="320"/>
                    <measurement group_id="O3" value="322"/>
                    <measurement group_id="O4" value="269"/>
                    <measurement group_id="O5" value="239"/>
                    <measurement group_id="O6" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site induration(N=1178,833,1068,777,607,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="153"/>
                    <measurement group_id="O6" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site swelling(N=1178,833,1068,777,607,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="128"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site tenderness(N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="246"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="171"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inj. site pain (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="477"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="360"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785"/>
                    <measurement group_id="O2" value="523"/>
                    <measurement group_id="O3" value="694"/>
                    <measurement group_id="O4" value="341"/>
                    <measurement group_id="O5" value="370"/>
                    <measurement group_id="O6" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eat. hab.(N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="261"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="162"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="312"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="186"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying (N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="345"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="175"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="353"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="187"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="211"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="114"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=1178,0,1068,0,607,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills shivering (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="118"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="197"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=0,833,0,777,0,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="337"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="222"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="317"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="159"/>
                    <measurement group_id="O6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever(38-38.9C)(N=1177,833,1068,775,607,421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="143"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever(39-39.9C)(N=1177,833,1068,775,607,421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever(≥40.0C)(N=1177,833,1068,775,607,421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analg.Antipyr.Used (N=1176,833,1068,777,607,422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="317"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="159"/>
                    <measurement group_id="O6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (Unprimed) With Unsolicited Adverse Events Reported After Any Vaccination</title>
        <description>Number of subjects aged 6 to &lt;36 months and in the overall age cohort (unprimed children aged 6 to &lt;72 months) experiencing each of the unsolicited adverse events (AEs) throughout the study</description>
        <time_frame>Study day 1 to Study day 181</time_frame>
        <population>The analysis was done on Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-Flu-control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIV-adj (6 to &lt;72 Months )</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O5">
            <title>Flu-control (6 to &lt;72 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O6">
            <title>Non-Flu-control (6 to &lt;72 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Unprimed) With Unsolicited Adverse Events Reported After Any Vaccination</title>
          <description>Number of subjects aged 6 to &lt;36 months and in the overall age cohort (unprimed children aged 6 to &lt;72 months) experiencing each of the unsolicited adverse events (AEs) throughout the study</description>
          <population>The analysis was done on Safety set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1177"/>
                <count group_id="O2" value="1069"/>
                <count group_id="O3" value="607"/>
                <count group_id="O4" value="2012"/>
                <count group_id="O5" value="1846"/>
                <count group_id="O6" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1045"/>
                    <measurement group_id="O2" value="938"/>
                    <measurement group_id="O3" value="530"/>
                    <measurement group_id="O4" value="1714"/>
                    <measurement group_id="O5" value="1566"/>
                    <measurement group_id="O6" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="262"/>
                    <measurement group_id="O5" value="203"/>
                    <measurement group_id="O6" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="122"/>
                    <measurement group_id="O5" value="169"/>
                    <measurement group_id="O6" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (Unprimed) Aged 6 to &lt;72 Months With Virus-Confirmed Influenza, Comparison of aTIV to Non-flu Vaccine Control and Flu-vaccine Control (Matched Strains)</title>
        <description>Virus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in subjects aged 6 to &lt;72 months (unprimed) for Absolute Efficacy.
For Relative efficacy, the comparison was made between adjuvanted influenza vaccine (TIV-adj) and flu vaccine control.</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control (6 to &lt;36 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu Control (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIV-adj (36 to &lt; 72 Months)</title>
            <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O5">
            <title>Non-flu Control (36 to &lt;72 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O6">
            <title>Flu Control (36 to &lt; 72 Months)</title>
            <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Unprimed) Aged 6 to &lt;72 Months With Virus-Confirmed Influenza, Comparison of aTIV to Non-flu Vaccine Control and Flu-vaccine Control (Matched Strains)</title>
          <description>Virus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in subjects aged 6 to &lt;72 months (unprimed) for Absolute Efficacy.
For Relative efficacy, the comparison was made between adjuvanted influenza vaccine (TIV-adj) and flu vaccine control.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="902"/>
                <count group_id="O4" value="698"/>
                <count group_id="O5" value="360"/>
                <count group_id="O6" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Matched strain(Season2007/08)N=187,97,93,136,67,71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Matched strain (Season2008/09)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                    <measurement group_id="O2" value="4.05"/>
                    <measurement group_id="O3" value="2.44"/>
                    <measurement group_id="O4" value="0.29"/>
                    <measurement group_id="O5" value="6.11"/>
                    <measurement group_id="O6" value="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute vaccine efficacy (VE) was calculated as (1- the relative risk)100%. Relative Risk for virus-confirmed symptomatic influenza illness in the TIV-adj group vs. the non-flu control group. VE denotes the vaccine efficacy, i.e. 1-Itest/Inon-flu ctrl, where I stands for the incidence of influenza.
Absolute efficacy of TIV-adj is at most 40% (i.e. the probability of an influenza in the test group relative to that in the non-flu vaccine group is at least 0.6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>81.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.24</ci_lower_limit>
            <ci_upper_limit>93.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Absolute vaccine efficacy (VE) was calculated as (1- the relative risk)100%. Relative Risk for virus-confirmed symptomatic influenza illness in the TIV-adj group vs. the non-flu control group. VE denotes the vaccine efficacy, i.e. 1-Itest/Inon-flu ctrl, where I stands for the incidence of influenza.
Absolute efficacy of TIV-adj is at most 40% (i.e. the probability of an influenza in the test group relative to that in the non-flu vaccine group is at least 0.6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>95.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.92</ci_lower_limit>
            <ci_upper_limit>98.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relative efficacy for TIV-adj was to be calculated as VE = (1-Itest/Ictrl)100%, where I is the incidence of influenza, i.e. percentage of subjects with virus-confirmed symptomatic influenza A or B illness, in the investigational agent (TIV-adj) group or in the flu vaccine control group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Relative efficacy for TIV-adj was to be calculated as VE = (1-Itest/Ictrl)100%, where I is the incidence of influenza, i.e. percentage of subjects with virus-confirmed symptomatic influenza A or B illness, in the investigational agent (TIV-adj) group or in the flu vaccine control group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (Unprimed) Aged 6 to &lt;72 Months With Virus-Confirmed Influenza, Comparison of aTIV to Non-flu Vaccine Control and Flu Vaccine Control (Any Strains).</title>
        <description>Virus-confirmed influenza illnesses (regardless of antigenic match to those contained in the vaccine) were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in subjects aged 6 to &lt;72 months (unprimed) for Absolute Efficacy.
For Relative efficacy, the comparison was made between adjuvanted influenza vaccine (TIV-adj) and flu vaccine control.</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu Control (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIV-adj (36 to &lt;72 Months)</title>
            <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O5">
            <title>Non-flu Control (36 to &lt; 72 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O6">
            <title>Flu Control (36 to &lt; 72 Months)</title>
            <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Unprimed) Aged 6 to &lt;72 Months With Virus-Confirmed Influenza, Comparison of aTIV to Non-flu Vaccine Control and Flu Vaccine Control (Any Strains).</title>
          <description>Virus-confirmed influenza illnesses (regardless of antigenic match to those contained in the vaccine) were assessed and compared between the adjuvanted influenza vaccine (TIV-adj) and non-influenza vaccines (Non-flu control) in subjects aged 6 to &lt;72 months (unprimed) for Absolute Efficacy.
For Relative efficacy, the comparison was made between adjuvanted influenza vaccine (TIV-adj) and flu vaccine control.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="902"/>
                <count group_id="O4" value="698"/>
                <count group_id="O5" value="360"/>
                <count group_id="O6" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Strain (Season 2007/08)N=187,97,93,136,67,71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.06"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.74"/>
                    <measurement group_id="O5" value="2.99"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Strain (Season 2008/09)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="4.26"/>
                    <measurement group_id="O3" value="2.77"/>
                    <measurement group_id="O4" value="0.43"/>
                    <measurement group_id="O5" value="6.39"/>
                    <measurement group_id="O6" value="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute vaccine efficacy (VE) was calculated as (1- the relative risk)100%. Relative Risk for virus-confirmed symptomatic influenza illness in the TIV-adj group vs. the non-flu control group. VE denotes the vaccine efficacy, i.e. 1-Itest/Inon-flu ctrl, where I stands for the population average incidence of influenza.
Absolute efficacy of TIV-adj is at most 40% (i.e. the probability of an influenza in the test group relative to that in the non-flu vaccine group is at least 0.6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>vaccine Efficacy</param_type>
            <param_value>79.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.78</ci_lower_limit>
            <ci_upper_limit>90.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Absolute vaccine efficacy (VE) was calculated as (1- the relative risk)100%. Relative Risk for virus-confirmed symptomatic influenza illness in the TIV-adj group vs. the non-flu control group. VE denotes the vaccine efficacy, i.e. 1-Itest/Inon-flu ctrl, where I stands for the incidence of influenza. Absolute efficacy of TIV-adj is at most 40% (i.e. the probability of an influenza in the test group relative to that in the non-flu vaccine group is at least 0.6)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>92.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.35</ci_lower_limit>
            <ci_upper_limit>97.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relative efficacy for TIV-adj was to be calculated as VE = (1-Itest/Ictrl)100%, where I is the incidence of influenza, i.e. percentage of subjects with virus-confirmed symptomatic influenza A or B illness, in the investigational agent (TIV-adj) group or in the flu vaccine control group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>64.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.21</ci_lower_limit>
            <ci_upper_limit>83.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Relative efficacy for TIV-adj was to be calculated as VE = (1-Itest/Ictrl)100%, where I is the incidence of influenza, i.e. percentage of subjects with virus-confirmed symptomatic influenza A or B illness, in the investigational agent (TIV-adj) group or in the flu vaccine control group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>85.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.95</ci_lower_limit>
            <ci_upper_limit>94.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (Unprimed) With Influenza Like Illnesses (ILIs) in the 6 to &lt;72 Months Age Cohort for Combined Seasons 2007/08 and 2008/09</title>
        <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine in 6 to &lt;72 month old subjects for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu Control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (Unprimed) With Influenza Like Illnesses (ILIs) in the 6 to &lt;72 Months Age Cohort for Combined Seasons 2007/08 and 2008/09</title>
          <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine in 6 to &lt;72 month old subjects for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1937"/>
                <count group_id="O2" value="1772"/>
                <count group_id="O3" value="993"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with ILI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425"/>
                    <measurement group_id="O2" value="436"/>
                    <measurement group_id="O3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="293"/>
                    <measurement group_id="O3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Recovered)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="431"/>
                    <measurement group_id="O3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Alive with sequelae)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Lost to follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (ILI persisting)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Influenza Like Illnesses (ILIs) in the 6 to &lt;36 Months and in Overall Age Cohort (Unprimed Subjects Aged 6 to &lt;72 Months) for Combined Seasons 2007/08 and 2008/09</title>
        <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt;36 months received 0.25 mL of each injection of Adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu-control (6 to &lt; 36 Months)</title>
            <description>Subjects aged 6 to &lt;36 months received 0.25 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O4">
            <title>TIV-adj (6 to &lt; 72 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O5">
            <title>Non-flu Control (6 to &lt;72 Months)</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O6">
            <title>Flu Control (6 to &lt; 72 Months)</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Influenza Like Illnesses (ILIs) in the 6 to &lt;36 Months and in Overall Age Cohort (Unprimed Subjects Aged 6 to &lt;72 Months) for Combined Seasons 2007/08 and 2008/09</title>
          <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1103"/>
                <count group_id="O2" value="566"/>
                <count group_id="O3" value="995"/>
                <count group_id="O4" value="1937"/>
                <count group_id="O5" value="993"/>
                <count group_id="O6" value="1772"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with ILI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="272"/>
                    <measurement group_id="O4" value="425"/>
                    <measurement group_id="O5" value="253"/>
                    <measurement group_id="O6" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="183"/>
                    <measurement group_id="O4" value="290"/>
                    <measurement group_id="O5" value="174"/>
                    <measurement group_id="O6" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inpatient visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Recovered)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="267"/>
                    <measurement group_id="O4" value="414"/>
                    <measurement group_id="O5" value="248"/>
                    <measurement group_id="O6" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Alive with sequelae)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Lost to follow-up)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (ILI persisting)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome (Not available)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Loss of Days of Usual Activity (Job, School, Day Care, Household/Family/Community Activities) Due to Influenza Like Illness (ILI) in Subjects in Aged 6 to &lt;72 and 6 to &lt;36 Months and in Direct Caregivers Living in the Household.</title>
        <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Loss of Days of Usual Activity (Job, School, Day Care, Household/Family/Community Activities) Due to Influenza Like Illness (ILI) in Subjects in Aged 6 to &lt;72 and 6 to &lt;36 Months and in Direct Caregivers Living in the Household.</title>
          <description>Virus-confirmed influenza illnesses were assessed and trivalent adjuvanted influenza vaccine (TIV-adj) was compared with Non-flu control vaccine and Flu-control vaccine for Influenza like illnesses for seasons 2007/08 and 2008/09.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="436"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean bed days (6 to &lt;72 mths)(N=419,250,426)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.3"/>
                    <measurement group_id="O2" value="2.3" spread="2.7"/>
                    <measurement group_id="O3" value="1.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean bed days (6 to &lt;36 mths)(N=274,160,263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.5"/>
                    <measurement group_id="O2" value="2.1" spread="2.4"/>
                    <measurement group_id="O3" value="1.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean inactive days(6 to &lt;72 mths)(N=417,249,427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="3.3"/>
                    <measurement group_id="O2" value="3.3" spread="3.5"/>
                    <measurement group_id="O3" value="2.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean inactive days(6 to &lt;36 mths)(N=273,160,264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.3"/>
                    <measurement group_id="O2" value="3.0" spread="3.6"/>
                    <measurement group_id="O3" value="2.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of Influenza Like Illness for Combined Seasons 2007/08 and 2008/09.</title>
        <description>The number of events of Influenza like Illness reported by subjects aged 6 to &lt;72 months was assessed for combined seasons 2007/08 and 2008/09</description>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Influenza Like Illness for Combined Seasons 2007/08 and 2008/09.</title>
          <description>The number of events of Influenza like Illness reported by subjects aged 6 to &lt;72 months was assessed for combined seasons 2007/08 and 2008/09</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="436"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean ILI events (6 to &lt;72 mths)(N=425,253,436)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.3" spread="0.6"/>
                    <measurement group_id="O3" value="1.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean ILI events (6 to &lt;36 mths)(N=280,163,272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.5"/>
                    <measurement group_id="O2" value="1.3" spread="0.6"/>
                    <measurement group_id="O3" value="1.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMRs, in Unprimed Subjects Aged 6 to &lt;36 Months or Season 2008/09 (Homologous and Heterologous Strains)</title>
        <description>The immunogenicity was assessed in terms of Geometric mean titer ratios (GMRs) of study day 29/study day 1, study day 50/study day 1, study day 181/study day 1 were evaluated.
The criteria for evaluation is GMR &gt;2.5</description>
        <time_frame>On study days 1, 29, 50 and 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMRs, in Unprimed Subjects Aged 6 to &lt;36 Months or Season 2008/09 (Homologous and Heterologous Strains)</title>
          <description>The immunogenicity was assessed in terms of Geometric mean titer ratios (GMRs) of study day 29/study day 1, study day 50/study day 1, study day 181/study day 1 were evaluated.
The criteria for evaluation is GMR &gt;2.5</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29:1 A/Brisbane/2007 (A/H1N1) (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="1.83" lower_limit="1.57" upper_limit="2.13"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.83" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 A/Brisbane/2007 (A/H1N1) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="70" upper_limit="98"/>
                    <measurement group_id="O2" value="4.55" lower_limit="3.84" upper_limit="5.39"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.87" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1 A/Brisbane/2007 (A/H1N1) (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.11" upper_limit="2.73"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.85" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 A/Brisbane/2007 (A/H3N2) (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.38" upper_limit="1.81"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.88" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 A/Brisbane/2007 (A/H3N2) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="73" upper_limit="102"/>
                    <measurement group_id="O2" value="5.57" lower_limit="4.73" upper_limit="6.55"/>
                    <measurement group_id="O3" value="1.04" lower_limit="0.83" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1 A/Brisbane/2007 (A/H3N1) (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="24" upper_limit="37"/>
                    <measurement group_id="O2" value="6.16" lower_limit="4.97" upper_limit="7.63"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.55" upper_limit="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 B/Florida/2006 (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="1.86" upper_limit="2.39"/>
                    <measurement group_id="O2" value="1.41" lower_limit="1.24" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.89" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 B/Florida/2006 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="O2" value="2.05" lower_limit="1.81" upper_limit="2.31"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.86" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1 B/Florida/2006 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" lower_limit="3.79" upper_limit="4.68"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.31" upper_limit="1.61"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.91" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1A/SolomonIsland/2006(A/H1N1)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.81" upper_limit="2.42"/>
                    <measurement group_id="O2" value="1.41" lower_limit="1.22" upper_limit="1.62"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.79" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1A/SolomonIsland/2006(A/H1N1)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="16" upper_limit="21"/>
                    <measurement group_id="O2" value="1.96" lower_limit="1.7" upper_limit="2.25"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.8" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181:1A/SolomonIsland/2006(A/H1N1)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" lower_limit="5.79" upper_limit="7.34"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.42" upper_limit="1.8"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.84" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 A/Wisconsin/2009 (A/H3N2)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" lower_limit="4.07" upper_limit="5.11"/>
                    <measurement group_id="O2" value="1.17" lower_limit="1.05" upper_limit="1.31"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.81" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 A/Wisconsin/2009 (A/H3N2)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="37" upper_limit="50"/>
                    <measurement group_id="O2" value="3.01" lower_limit="2.59" upper_limit="3.51"/>
                    <measurement group_id="O3" value="1.04" lower_limit="0.84" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181:1 A/Wisconsin/2009 (A/H3N2)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="25"/>
                    <measurement group_id="O2" value="5.06" lower_limit="4.03" upper_limit="6.37"/>
                    <measurement group_id="O3" value="2.22" lower_limit="1.61" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 B/Brisbane/2008 (N=164,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="1.04" upper_limit="1.11"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.098" upper_limit="1.05"/>
                    <measurement group_id="O3" value="1" lower_limit="0.96" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 B/Brisbane/2008 (N=159,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.8" upper_limit="2.08"/>
                    <measurement group_id="O2" value="1.11" lower_limit="1.03" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.93" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181:1 B/Brisbane/2008 (N=160,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.98" upper_limit="1.11"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.98" upper_limit="1.11"/>
                    <measurement group_id="O3" value="1.26" lower_limit="1.15" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of Geometric Mean Titers (GMTs), in Unprimed Subjects Aged 6 to &lt;36 Months for Season 2008/09 (Homologous and Heterologous Strains)</title>
        <description>Immunogenicity was analyzed in terms of Geometric Mean Titers (GMTs) as measured by hemagglutination inhibition (HI) assay. For each strain and each vaccine group, least squares GMTs, associated 2-sided 95% confidence interval were determined for all time points.
Superiority analysis: GMT-TIV-adj/GMT-Flu-control &gt;1 should be elicited to show that GMT-TIV-adj is superior to GMT-Flu-control</description>
        <time_frame>On study days 1, 29, 50 and 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of Geometric Mean Titers (GMTs), in Unprimed Subjects Aged 6 to &lt;36 Months for Season 2008/09 (Homologous and Heterologous Strains)</title>
          <description>Immunogenicity was analyzed in terms of Geometric Mean Titers (GMTs) as measured by hemagglutination inhibition (HI) assay. For each strain and each vaccine group, least squares GMTs, associated 2-sided 95% confidence interval were determined for all time points.
Superiority analysis: GMT-TIV-adj/GMT-Flu-control &gt;1 should be elicited to show that GMT-TIV-adj is superior to GMT-Flu-control</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 A/Brisbane/2007 (A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" lower_limit="5.33" upper_limit="7.24"/>
                    <measurement group_id="O2" value="7.52" lower_limit="6.45" upper_limit="8.76"/>
                    <measurement group_id="O3" value="5.93" lower_limit="4.8" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 A/Brisbane/2007 (A/H1N1) (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="82" upper_limit="136"/>
                    <measurement group_id="O2" value="14" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O3" value="6.13" lower_limit="4.33" upper_limit="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/Brisbane/2007 (A/H1N1) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513" lower_limit="405" upper_limit="652"/>
                    <measurement group_id="O2" value="35" lower_limit="27" upper_limit="44"/>
                    <measurement group_id="O3" value="6.57" lower_limit="4.71" upper_limit="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 A/Brisbane/2007 (A/H1N1) (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" lower_limit="95" upper_limit="146"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O3" value="6.1" lower_limit="4.51" upper_limit="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/Brisbane/2007 (A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" lower_limit="5.13" upper_limit="6.67"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.09" upper_limit="6.6"/>
                    <measurement group_id="O3" value="5.66" lower_limit="4.73" upper_limit="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 A/Brisbane/2007 (A/H3N2) (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="76" upper_limit="107"/>
                    <measurement group_id="O2" value="9.17" lower_limit="7.71" upper_limit="11"/>
                    <measurement group_id="O3" value="6.04" lower_limit="4.75" upper_limit="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/Brisbane/2007 (A/H3N2) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510" lower_limit="426" upper_limit="609"/>
                    <measurement group_id="O2" value="32" lower_limit="27" upper_limit="39"/>
                    <measurement group_id="O3" value="6" lower_limit="4.68" upper_limit="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 A/Brisbane/2007 (A/H3N2) (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" lower_limit="141" upper_limit="220"/>
                    <measurement group_id="O2" value="36" lower_limit="29" upper_limit="45"/>
                    <measurement group_id="O3" value="12" lower_limit="8.74" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 B/Florida/2006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="5.59" upper_limit="6.45"/>
                    <measurement group_id="O2" value="6" lower_limit="5.59" upper_limit="6.44"/>
                    <measurement group_id="O3" value="5.87" lower_limit="5.32" upper_limit="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 B/Florida/2006 (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="8.45" lower_limit="7.11" upper_limit="10"/>
                    <measurement group_id="O3" value="6.19" lower_limit="4.87" upper_limit="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 B/Florida/2006 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="74" upper_limit="100"/>
                    <measurement group_id="O2" value="12" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O3" value="6.09" lower_limit="4.95" upper_limit="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 B/Florida/2006 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="22" upper_limit="29"/>
                    <measurement group_id="O2" value="8.72" lower_limit="7.65" upper_limit="9.95"/>
                    <measurement group_id="O3" value="6.21" lower_limit="5.16" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/SolomonIslands/2006(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" lower_limit="5.56" upper_limit="7.98"/>
                    <measurement group_id="O2" value="8.19" lower_limit="6.85" upper_limit="9.8"/>
                    <measurement group_id="O3" value="6.24" lower_limit="4.87" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 A/SolomonIslands/2006(A/H1N1)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O2" value="12" lower_limit="8.69" upper_limit="15"/>
                    <measurement group_id="O3" value="6.08" lower_limit="4.12" upper_limit="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/SolomonIslands/2006(A/H1N1)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="94" upper_limit="157"/>
                    <measurement group_id="O2" value="16" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="O3" value="6.1" lower_limit="4.27" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 A/SolomonIslands/2006(A/H1N1)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="34" upper_limit="55"/>
                    <measurement group_id="O2" value="13" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="O3" value="6.2" lower_limit="4.46" upper_limit="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/Wisconsin/2009 (A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" lower_limit="5.26" upper_limit="7.06"/>
                    <measurement group_id="O2" value="6.74" lower_limit="5.83" upper_limit="7.8"/>
                    <measurement group_id="O3" value="6.16" lower_limit="5.03" upper_limit="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 A/Wisconsin/2009 (A/H3N2)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="23" upper_limit="33"/>
                    <measurement group_id="O2" value="7.86" lower_limit="6.57" upper_limit="9.39"/>
                    <measurement group_id="O3" value="5.87" lower_limit="4.59" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/Wisconsin/2009 (A/H3N2)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261" lower_limit="218" upper_limit="313"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="24"/>
                    <measurement group_id="O3" value="6.47" lower_limit="5.03" upper_limit="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 A/Wisconsin/2009 (A/H3N2)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" lower_limit="97" upper_limit="156"/>
                    <measurement group_id="O2" value="34" lower_limit="27" upper_limit="43"/>
                    <measurement group_id="O3" value="14" lower_limit="9.81" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 B/Brisbane/2008 (N=165,165,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 B/Brisbane/2008 (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" lower_limit="5.21" upper_limit="5.56"/>
                    <measurement group_id="O2" value="5.08" lower_limit="4.91" upper_limit="5.24"/>
                    <measurement group_id="O3" value="5" lower_limit="4.78" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 B/Brisbane/2008 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" lower_limit="8.96" upper_limit="10"/>
                    <measurement group_id="O2" value="5.55" lower_limit="5.16" upper_limit="5.97"/>
                    <measurement group_id="O3" value="5.12" lower_limit="4.63" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 B/Brisbane/2008 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="4.89" upper_limit="5.54"/>
                    <measurement group_id="O2" value="5.23" lower_limit="4.92" upper_limit="5.56"/>
                    <measurement group_id="O3" value="6.28" lower_limit="5.75" upper_limit="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>7.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.42</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11</ci_lower_limit>
            <ci_upper_limit>21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>6.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.83</ci_lower_limit>
            <ci_upper_limit>8.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>9.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.76</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>4.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.64</ci_lower_limit>
            <ci_upper_limit>6.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[B/Florida/2006]</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[B/Florida/2006]</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[B/Florida/2006]</param_type>
            <param_value>6.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.72</ci_lower_limit>
            <ci_upper_limit>8.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[B/Florida/2006]</param_type>
            <param_value>2.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.44</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Solomon Islands/2006 (A/H1N1]</param_type>
            <param_value>7.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.33</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>3.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>4.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT[A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>3.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.78</ci_lower_limit>
            <ci_upper_limit>4.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10</ci_lower_limit>
            <ci_upper_limit>16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.61</ci_lower_limit>
            <ci_upper_limit>4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;36 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (95% CI) of Unprimed Subjects Aged 6 to &lt;36 Months With HI Titer ≥1:40 in Season 2008/09 HI Assay(Homologous and Heterologous Strains)</title>
        <description>Percentage of subjects achieving seroprotection (i.e., with HI titer ≥1:40) at study day 1, study day 29, study day 50 and a study day 181 and associated 95% CI. The lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%.</description>
        <time_frame>On study days 1, 29, 50, 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of Adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (95% CI) of Unprimed Subjects Aged 6 to &lt;36 Months With HI Titer ≥1:40 in Season 2008/09 HI Assay(Homologous and Heterologous Strains)</title>
          <description>Percentage of subjects achieving seroprotection (i.e., with HI titer ≥1:40) at study day 1, study day 29, study day 50 and a study day 181 and associated 95% CI. The lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 A/Brisbane/2007 (A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="11" lower_limit="7" upper_limit="17"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 A/Brisbane/2007(A/H1N1)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O2" value="20" lower_limit="14" upper_limit="27"/>
                    <measurement group_id="O3" value="6" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/Brisbane/2007 (A/H1N1) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="38" lower_limit="31" upper_limit="46"/>
                    <measurement group_id="O3" value="6" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H1N1)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="25" lower_limit="19" upper_limit="33"/>
                    <measurement group_id="O3" value="6" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 A/Brisbane/2007(A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 A/Brisbane/2007(A/H3N2)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 A/Brisbane/2007(A/H3N2)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="45" lower_limit="37" upper_limit="53"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H3N2)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="45" lower_limit="37" upper_limit="53"/>
                    <measurement group_id="O3" value="21" lower_limit="13" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 B/Florida/2006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O3" value="1" lower_limit="0.03" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 B/Florida/2006 (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8" upper_limit="18"/>
                    <measurement group_id="O2" value="12" lower_limit="8" upper_limit="18"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 B/Florida/2006 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181B/Florida/2006 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="33" upper_limit="48"/>
                    <measurement group_id="O2" value="13" lower_limit="9" upper_limit="20"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/SolomonIslands/2006(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="11" lower_limit="7" upper_limit="17"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29A/Sol.Islands/2006(A/H1N1)(N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10" upper_limit="21"/>
                    <measurement group_id="O2" value="13" lower_limit="9" upper_limit="20"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50A/Sol.Islands/2006(A/H1N1) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O2" value="24" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D181A/Sol.Islands/2006(A/H1N1) (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="53" upper_limit="68"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/Wisconsin/2009 (A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 A/Wisconsin/2009(A/H3N2) (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="30" upper_limit="45"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 A/Wisconsin/2009(A/H3N2) (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="30" lower_limit="23" upper_limit="37"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Wisconsin/2009(A/H3N2) (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="42" lower_limit="34" upper_limit="50"/>
                    <measurement group_id="O3" value="23" lower_limit="14" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 B/Brisbane/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 B/Brisbane/2008 (N=165,163,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.015" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 B/Brisbane/2008 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 B/Brisbane/2008 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.016" upper_limit="3"/>
                    <measurement group_id="O3" value="6" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (95% CI) of Unprimed Subjects Aged 6 to &lt;36 Months With Seroconversion From Baseline, for Season 2008/09 (Homologous and Heterologous Strains)</title>
        <description>HI assay was used for the analysis. Seroconversion is defined as negative pre-vaccination serum (&lt;10)/ post-vaccination HI titer ≥1:40.
Seroconversion is defined as either pre-vaccination HI titer &lt;10 and a post-vaccination HI titer ≥1:40 or a prevaccination HI titer ≥10 and a minimum four-fold rise in post-vaccination HI antibody titer.
The lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%.</description>
        <time_frame>On study days 1, 29, 50, 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of Adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (95% CI) of Unprimed Subjects Aged 6 to &lt;36 Months With Seroconversion From Baseline, for Season 2008/09 (Homologous and Heterologous Strains)</title>
          <description>HI assay was used for the analysis. Seroconversion is defined as negative pre-vaccination serum (&lt;10)/ post-vaccination HI titer ≥1:40.
Seroconversion is defined as either pre-vaccination HI titer &lt;10 and a post-vaccination HI titer ≥1:40 or a prevaccination HI titer ≥10 and a minimum four-fold rise in post-vaccination HI antibody titer.
The lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day29 A/Brisbane/2007(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="26"/>
                    <measurement group_id="O3" value="1" lower_limit="0.031" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 A/Brisbane/2007(A/H1N1)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="38" lower_limit="30" upper_limit="46"/>
                    <measurement group_id="O3" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H1N1)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="24" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O3" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 A/Brisbane/2007(A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="88" upper_limit="97"/>
                    <measurement group_id="O2" value="10" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O3" value="1" lower_limit="0.031" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 A/Brisbane/2007(A/H3N2)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="44" lower_limit="36" upper_limit="52"/>
                    <measurement group_id="O3" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H3N2)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="42" lower_limit="35" upper_limit="50"/>
                    <measurement group_id="O3" value="19" lower_limit="11" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 B/Florida/2006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8" upper_limit="18"/>
                    <measurement group_id="O2" value="12" lower_limit="8" upper_limit="18"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 B/Florida/2006 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181B/Florida/2006 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="31" upper_limit="46"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="18"/>
                    <measurement group_id="O3" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29A/Sol.Islands/2006(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9" upper_limit="20"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="19"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50A/Sol.Islands/2006(A/H1N1)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O2" value="23" lower_limit="17" upper_limit="30"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Sol.Islands/2006(A/H1N1)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="52" upper_limit="68"/>
                    <measurement group_id="O2" value="18" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 A/Wisconsin/2009(A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="28" upper_limit="44"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 A/Wisconsin/2009(A/H3N2)(N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="27" lower_limit="20" upper_limit="35"/>
                    <measurement group_id="O3" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Wisconsin/2009(A/H3N2)(N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="39" lower_limit="31" upper_limit="47"/>
                    <measurement group_id="O3" value="20" lower_limit="12" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 B/Brisbane/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.015" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 B/Brisbane/2008 (N=160,162,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 B/Brisbane/2008 (N=161,163,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.016" upper_limit="3"/>
                    <measurement group_id="O3" value="6" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMTs, in Unprimed Subjects Aged 6 to &lt;72 Months for Season 2008/09 (Homologous and Heterologous Strains)</title>
        <description>Immunogenicity was analyzed in terms of Geometric Mean Titers (GMTs) as measured by hemagglutination inhibition (HI) assay. For each strain and each vaccine group, least squares GMTs, associated 2-sided 95% confidence interval were determined for all time points Superiority analysis: GMT-TIV-adj/GMT-Flu-control &gt;1 and GMT-TIV-adj/GMT-Non Flu-control &gt;1 should be elicited to show that GMT-TIV-adj is superior to GMT-Flu-control/Non Flu-control.</description>
        <time_frame>On study days 1, 29, 50 , 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMTs, in Unprimed Subjects Aged 6 to &lt;72 Months for Season 2008/09 (Homologous and Heterologous Strains)</title>
          <description>Immunogenicity was analyzed in terms of Geometric Mean Titers (GMTs) as measured by hemagglutination inhibition (HI) assay. For each strain and each vaccine group, least squares GMTs, associated 2-sided 95% confidence interval were determined for all time points Superiority analysis: GMT-TIV-adj/GMT-Flu-control &gt;1 and GMT-TIV-adj/GMT-Non Flu-control &gt;1 should be elicited to show that GMT-TIV-adj is superior to GMT-Flu-control/Non Flu-control.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 A/Brisbane/2007 (A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.63" lower_limit="8.28" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="8.59" upper_limit="12"/>
                    <measurement group_id="O3" value="9.48" lower_limit="7.67" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29A/Brisbane/2007(A/H1N1) (N=316,313,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232" lower_limit="185" upper_limit="291"/>
                    <measurement group_id="O2" value="36" lower_limit="29" upper_limit="45"/>
                    <measurement group_id="O3" value="9.42" lower_limit="6.85" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50A/Brisbane/2007(A/H1N1) (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="735" lower_limit="608" upper_limit="888"/>
                    <measurement group_id="O2" value="89" lower_limit="74" upper_limit="108"/>
                    <measurement group_id="O3" value="9.91" lower_limit="7.58" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H1N1) (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="155" upper_limit="225"/>
                    <measurement group_id="O2" value="43" lower_limit="35" upper_limit="51"/>
                    <measurement group_id="O3" value="9.65" lower_limit="7.41" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1A/Brisbane/2007(A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="12" lower_limit="9.83" upper_limit="14"/>
                    <measurement group_id="O3" value="12" lower_limit="8.98" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 A/Brisbane/2007 (A/H3N2) (N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="167" upper_limit="261"/>
                    <measurement group_id="O2" value="33" lower_limit="26" upper_limit="41"/>
                    <measurement group_id="O3" value="12" lower_limit="8.83" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/Brisbane/2007 (A/H3N2) (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="762" lower_limit="634" upper_limit="915"/>
                    <measurement group_id="O2" value="95" lower_limit="79" upper_limit="115"/>
                    <measurement group_id="O3" value="12" lower_limit="9.18" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 A/Brisbane/2007 (A/H3N2) (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295" lower_limit="245" upper_limit="356"/>
                    <measurement group_id="O2" value="94" lower_limit="78" upper_limit="114"/>
                    <measurement group_id="O3" value="26" lower_limit="20" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 B/Florida/2006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" lower_limit="6.01" upper_limit="6.75"/>
                    <measurement group_id="O2" value="6.57" lower_limit="6.2" upper_limit="6.96"/>
                    <measurement group_id="O3" value="6.41" lower_limit="5.92" upper_limit="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 B/Florida/2006 (N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="18" upper_limit="25"/>
                    <measurement group_id="O2" value="14" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="O3" value="6.54" lower_limit="5.26" upper_limit="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 B/Florida/2006 (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="97" upper_limit="123"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="25"/>
                    <measurement group_id="O3" value="6.67" lower_limit="5.64" upper_limit="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 B/Florida/2006 (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="29" upper_limit="36"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O3" value="6.92" lower_limit="6.01" upper_limit="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/SolomonIslands/2006(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.47" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="9.89" upper_limit="14"/>
                    <measurement group_id="O3" value="10" lower_limit="8.16" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 A/SolomonIslands/2006(A/H1N1)(N=316,313,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="30" upper_limit="53"/>
                    <measurement group_id="O2" value="23" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O3" value="10" lower_limit="7.12" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 A/SolomonIslands/2006(A/H1N1)(N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228" lower_limit="182" upper_limit="287"/>
                    <measurement group_id="O2" value="41" lower_limit="33" upper_limit="51"/>
                    <measurement group_id="O3" value="11" lower_limit="7.63" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/SolomonIslands/2006(A/H1N1)(N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="70" upper_limit="109"/>
                    <measurement group_id="O2" value="28" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="O3" value="11" lower_limit="7.76" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 A/Wisconsin/2009 (A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="O3" value="13" lower_limit="9.97" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 A/Wisconsin/2009 (A/H3N2) (N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="75" upper_limit="127"/>
                    <measurement group_id="O2" value="31" lower_limit="24" upper_limit="40"/>
                    <measurement group_id="O3" value="13" lower_limit="8.74" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 A/Wisconsin/2009 (A/H3N2) (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518" lower_limit="420" upper_limit="639"/>
                    <measurement group_id="O2" value="70" lower_limit="57" upper_limit="87"/>
                    <measurement group_id="O3" value="14" lower_limit="10" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 A/Wisconsin/2009 (A/H3N2) (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261" lower_limit="212" upper_limit="322"/>
                    <measurement group_id="O2" value="98" lower_limit="79" upper_limit="121"/>
                    <measurement group_id="O3" value="34" lower_limit="26" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 B/Brisbane/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="4.99" upper_limit="5.11"/>
                    <measurement group_id="O2" value="5.05" lower_limit="5" upper_limit="5.11"/>
                    <measurement group_id="O3" value="5.08" lower_limit="5" upper_limit="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 B/Brisbane/2008 (N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" lower_limit="5.97" upper_limit="6.66"/>
                    <measurement group_id="O2" value="5.57" lower_limit="5.28" upper_limit="5.89"/>
                    <measurement group_id="O3" value="5.11" lower_limit="4.74" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 B/Brisbane/2008 (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="13"/>
                    <measurement group_id="O2" value="6.69" lower_limit="6.23" upper_limit="7.17"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.71" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181 B/Brisbane/2008 (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" lower_limit="5.77" upper_limit="6.49"/>
                    <measurement group_id="O2" value="5.67" lower_limit="5.35" upper_limit="6.01"/>
                    <measurement group_id="O3" value="6.12" lower_limit="5.64" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>6.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.69</ci_lower_limit>
            <ci_upper_limit>8.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>8.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.36</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Brisbane/2007 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H1N1)]</param_type>
            <param_value>4.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.38</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Brisbane/2007 (A/H3N2) in terms of Geometric Mean Titers GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>6.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.72</ci_lower_limit>
            <ci_upper_limit>8.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>7.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.2</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Brisbane/2007 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Brisbane/2007 (A/H3N2)]</param_type>
            <param_value>3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.42</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Florida/2006]</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Florida/2006]</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Florida/2006]</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.25</ci_lower_limit>
            <ci_upper_limit>5.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain B/Florida/2006 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Florida/2006]</param_type>
            <param_value>2.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>2.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day1 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>5.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.08</ci_lower_limit>
            <ci_upper_limit>7.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Solomon Islands/2006 (A/H1N1) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Solomon Islands/2006 (A/H1N1)]</param_type>
            <param_value>3.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>4.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>7.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.51</ci_lower_limit>
            <ci_upper_limit>9.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain A/Wisconsin/2009 (A/H3N2) in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [A/Wisconsin/2009 (A/H3N2)]</param_type>
            <param_value>2.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 1 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 29 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 50 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.63</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To demonstrate superiority of immunogenicity of TIV-adj compared to Flu-control on Day 181 for strain B/Brisbane/2008 in terms of GMTs in subjects aged 6 to &lt;72 months by HI assay.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT [B/Brisbane/2008]</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMRs, in Unprimed Subjects Aged 6 to &lt;72 Months for Season 2008/09 (Homologous and Heterologous Strains)</title>
        <description>Hemagglutination Inhibition (HI) assay was used for the analysis. Geometric mean titer ratios (GMRs) of study day 29/study day 1, study day 50/study day 1, study day 181/study day 1 were evaluated.
The criteria for evaluation is GMR &gt;2.5</description>
        <time_frame>On study days 1, 29, 50, 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of aTIV, Compared to Flu and Non-Flu-control, in Terms of GMRs, in Unprimed Subjects Aged 6 to &lt;72 Months for Season 2008/09 (Homologous and Heterologous Strains)</title>
          <description>Hemagglutination Inhibition (HI) assay was used for the analysis. Geometric mean titer ratios (GMRs) of study day 29/study day 1, study day 50/study day 1, study day 181/study day 1 were evaluated.
The criteria for evaluation is GMR &gt;2.5</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29:1A/Brisbane/2007(A/H1N1;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="21" upper_limit="27"/>
                    <measurement group_id="O2" value="3.6" lower_limit="3.17" upper_limit="4.08"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.83" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1A/Brisbane/2007(A/H1N1;N=10,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="67" upper_limit="86"/>
                    <measurement group_id="O2" value="9" lower_limit="7.89" upper_limit="10"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.84" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1A/Brisbane/2007(A/H1N1;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="O2" value="4.31" lower_limit="3.89" upper_limit="4.77"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.88" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1A/Brisbane/2007(A/H3N2;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="15" upper_limit="19"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.4" upper_limit="3.09"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.86" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D50:1A/Brisbane/2007(A/H3N2;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="52" upper_limit="69"/>
                    <measurement group_id="O2" value="8.03" lower_limit="6.93" upper_limit="9.3"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.8" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1A/Brisbane/2007(A/H3N2;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="20" upper_limit="28"/>
                    <measurement group_id="O2" value="7.96" lower_limit="6.71" upper_limit="9.44"/>
                    <measurement group_id="O3" value="2.21" lower_limit="1.73" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1B/Florida/2006(N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" lower_limit="2.94" upper_limit="3.75"/>
                    <measurement group_id="O2" value="2.06" lower_limit="1.83" upper_limit="2.33"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.87" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1B/Florida/2006(N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="15" upper_limit="19"/>
                    <measurement group_id="O2" value="3.29" lower_limit="2.98" upper_limit="3.63"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.9" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1B/Florida/2006(N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" lower_limit="4.67" upper_limit="5.46"/>
                    <measurement group_id="O2" value="1.92" lower_limit="1.78" upper_limit="2.08"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.95" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1A/Sol.Island/2006(A/H1N1;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" lower_limit="3.09" upper_limit="3.98"/>
                    <measurement group_id="O2" value="1.96" lower_limit="1.72" upper_limit="2.22"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.83" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1A/Sol.Island/2006A/H1N1;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="18" upper_limit="22"/>
                    <measurement group_id="O2" value="3.49" lower_limit="3.12" upper_limit="3.89"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.83" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1A/Sol.Island/2006A/H1N1;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" lower_limit="6.98" upper_limit="8.34"/>
                    <measurement group_id="O2" value="2.41" lower_limit="2.2" upper_limit="2.63"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.89" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1A/Wisconsin/2009(A/H3N2;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" lower_limit="5.92" upper_limit="7.34"/>
                    <measurement group_id="O2" value="2.04" lower_limit="1.83" upper_limit="2.27"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.8" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1A/Wisconsin/2009(A/H3N2;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="30" upper_limit="38"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.07" upper_limit="5.2"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.83" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1A/Wisconsin/2009(A/H3N2;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="6.39" lower_limit="5.36" upper_limit="7.6"/>
                    <measurement group_id="O3" value="2.59" lower_limit="2" upper_limit="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1B/Brisbane/2008(N=315,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.19" upper_limit="1.31"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.05" upper_limit="1.16"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.94" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1B/Brisbane/2008(N=309,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="2.23" upper_limit="2.55"/>
                    <measurement group_id="O2" value="1.32" lower_limit="1.24" upper_limit="1.42"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.93" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1B/Brisbane/2008(N=308,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="1.15" upper_limit="1.28"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.06" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.21" lower_limit="1.11" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With HI Titers ≥ 1:40 in Unprimed Subjects 6 to &lt;72 Months of Age for Season 2008/09 Homologous and Heterologous Strains</title>
        <description>Hemagglutination Inhibition (HI) assay was used for the analysis.
Percentage of subjects achieving seroprotection (i.e., with HI titer ≥1:40) at study day 1, study day 29, study day 50 and a study day 181 and associated 95% Confidence Intervals. The lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%.</description>
        <time_frame>On study days 1, 29, 50, 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HI Titers ≥ 1:40 in Unprimed Subjects 6 to &lt;72 Months of Age for Season 2008/09 Homologous and Heterologous Strains</title>
          <description>Hemagglutination Inhibition (HI) assay was used for the analysis.
Percentage of subjects achieving seroprotection (i.e., with HI titer ≥1:40) at study day 1, study day 29, study day 50 and a study day 181 and associated 95% Confidence Intervals. The lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥1:40 should meet or exceed 70%.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1 A/Brisbane/2007(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="25"/>
                    <measurement group_id="O2" value="21" lower_limit="17" upper_limit="26"/>
                    <measurement group_id="O3" value="16" lower_limit="11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29A/Brisbane/2007(A/H1N1;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O2" value="40" lower_limit="35" upper_limit="46"/>
                    <measurement group_id="O3" value="17" lower_limit="11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50A/Brisbane/2007(A/H1N1;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="59" lower_limit="54" upper_limit="65"/>
                    <measurement group_id="O3" value="17" lower_limit="12" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H1N1;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="49" lower_limit="43" upper_limit="54"/>
                    <measurement group_id="O3" value="18" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1A/Brisbane/2007(A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="18" upper_limit="28"/>
                    <measurement group_id="O2" value="22" lower_limit="17" upper_limit="27"/>
                    <measurement group_id="O3" value="20" lower_limit="14" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29A/Brisbane/2007(A/H3N2;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O2" value="35" lower_limit="30" upper_limit="40"/>
                    <measurement group_id="O3" value="21" lower_limit="15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50A/Brisbane/2007(A/H3N2;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="65" lower_limit="60" upper_limit="71"/>
                    <measurement group_id="O3" value="21" lower_limit="14" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181A/Brisbane/2007(A/H3N2;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="65" lower_limit="60" upper_limit="70"/>
                    <measurement group_id="O3" value="41" lower_limit="33" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1B/Florida/2006</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29B/Florida/2006(N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="23" upper_limit="33"/>
                    <measurement group_id="O2" value="26" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50B/Florida/2006(N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89" upper_limit="95"/>
                    <measurement group_id="O2" value="38" lower_limit="33" upper_limit="44"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181B/Florida/2006(N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="46" upper_limit="57"/>
                    <measurement group_id="O2" value="23" lower_limit="18" upper_limit="28"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1A/Sol.Islands/2006(A/H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="16" upper_limit="26"/>
                    <measurement group_id="O2" value="22" lower_limit="17" upper_limit="27"/>
                    <measurement group_id="O3" value="18" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D29A/Sol.Islands/2006(A/H1N1;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="27" upper_limit="38"/>
                    <measurement group_id="O2" value="24" lower_limit="20" upper_limit="29"/>
                    <measurement group_id="O3" value="18" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D50A/Sol.islands/2006(A/H1N1;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="45" lower_limit="39" upper_limit="51"/>
                    <measurement group_id="O3" value="18" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D181A/Sol.Islands/2006(A/H1N1;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="67" upper_limit="77"/>
                    <measurement group_id="O2" value="34" lower_limit="29" upper_limit="40"/>
                    <measurement group_id="O3" value="18" lower_limit="12" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1A/Wisconsin/2009(A/H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="O2" value="25" lower_limit="20" upper_limit="30"/>
                    <measurement group_id="O3" value="21" lower_limit="15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29A/Wisconsin/2009(A/H3N2;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="54" upper_limit="66"/>
                    <measurement group_id="O2" value="29" lower_limit="24" upper_limit="34"/>
                    <measurement group_id="O3" value="21" lower_limit="14" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50A/Wisconsin/2009(A/H3N2;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="54" lower_limit="48" upper_limit="59"/>
                    <measurement group_id="O3" value="21" lower_limit="15" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D181A/Wisconsin/2009(A/H3N2;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="63" lower_limit="57" upper_limit="68"/>
                    <measurement group_id="O3" value="43" lower_limit="35" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1B/Brisbane/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="0.016" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29B/Brisbane/2008(N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="1" lower_limit="0.016" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50B/Brisbane/2008(N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181B/Brisbane/2008(N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Seroconversion and Vaccine Group Differences in Unprimed Subjects 6 to &lt;72 Months of Age for Season 2008/09 (Homologous and Heterologous Strains)</title>
        <description>HI assay was used for the analysis. Seroconversion is defined as negative pre-vaccination serum (&lt;10)/ post-vaccination HI titer ≥1:40.
Seroconversion is defined as either pre-vaccination HI titer &lt;10 and a post-vaccination HI titer ≥1:40 or a prevaccination HI titer ≥10 and a minimum 4-fold rise in post-vaccination HI antibody titer. The lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%.</description>
        <time_frame>On study days 1, 29, 50, 181</time_frame>
        <population>The analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu-control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroconversion and Vaccine Group Differences in Unprimed Subjects 6 to &lt;72 Months of Age for Season 2008/09 (Homologous and Heterologous Strains)</title>
          <description>HI assay was used for the analysis. Seroconversion is defined as negative pre-vaccination serum (&lt;10)/ post-vaccination HI titer ≥1:40.
Seroconversion is defined as either pre-vaccination HI titer &lt;10 and a post-vaccination HI titer ≥1:40 or a prevaccination HI titer ≥10 and a minimum 4-fold rise in post-vaccination HI antibody titer. The lower bound of the two-sided 95% confidence interval (CI) for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40%.</description>
          <population>The analysis was done on Full Analysis Set</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29:1 A/Brisbane/2007 (A/H1N1; N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O2" value="40" lower_limit="34" upper_limit="45"/>
                    <measurement group_id="O3" value="1" lower_limit="0.016" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 A/Brisbane/2007 (A/H1N1; N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="59" lower_limit="53" upper_limit="64"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1 A/Brisbane/2007 (A/H1N1; N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="48" lower_limit="42" upper_limit="53"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 A/Brisbane/2007 (A/H3N2; N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O2" value="31" lower_limit="26" upper_limit="37"/>
                    <measurement group_id="O3" value="1" lower_limit="0.016" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 A/Brisbane/2007 (A/H3N2; N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="63" lower_limit="57" upper_limit="68"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1 A/Brisbane/2007 (A/H3N2; N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="90" upper_limit="96"/>
                    <measurement group_id="O2" value="56" lower_limit="51" upper_limit="62"/>
                    <measurement group_id="O3" value="23" lower_limit="17" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 B/Florida/2006 (N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="23" upper_limit="33"/>
                    <measurement group_id="O2" value="26" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 B/Florida/2006 (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="89" upper_limit="95"/>
                    <measurement group_id="O2" value="38" lower_limit="32" upper_limit="43"/>
                    <measurement group_id="O3" value="1" lower_limit="0.017" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181:1 B/Florida/2006 (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="44" upper_limit="56"/>
                    <measurement group_id="O2" value="19" lower_limit="15" upper_limit="24"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1A/SolomonIsland/2006(A/H1N1;N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="27" upper_limit="37"/>
                    <measurement group_id="O2" value="24" lower_limit="19" upper_limit="29"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1A/SolomonIsland/2006(A/H1N1;N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O2" value="44" lower_limit="39" upper_limit="50"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181:1A/SolomonIsland/2006(A/H1N1;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="66" upper_limit="76"/>
                    <measurement group_id="O2" value="33" lower_limit="27" upper_limit="38"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 A/Wisconsin/2009 (A/H3N2; N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="53" upper_limit="64"/>
                    <measurement group_id="O2" value="23" lower_limit="19" upper_limit="28"/>
                    <measurement group_id="O3" value="1" lower_limit="0.016" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 A/Wisconsin/2009 (A/H3N2; N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="49" lower_limit="43" upper_limit="54"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181:1 A/Wisconsin/2009 (A/H3N2;N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="89" upper_limit="95"/>
                    <measurement group_id="O2" value="52" lower_limit="46" upper_limit="58"/>
                    <measurement group_id="O3" value="25" lower_limit="18" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29:1 B/Brisbane/2008 (N=316,313,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50:1 B/Brisbane/2008 (N=310,309,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day181:1 B/Brisbane/2008 (N=309,310,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Local and Systemic Reactions for Egg and Cell Derived Inactivated Novel Swine Origin A/H1N1 Subunit Influenza Vaccines After Each Vaccination for All Seasons</title>
        <time_frame>7 days post-vaccination</time_frame>
        <population>Adequate data was not available to conduct this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Flu-control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
          <group group_id="O3">
            <title>Non-flu Control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Local and Systemic Reactions for Egg and Cell Derived Inactivated Novel Swine Origin A/H1N1 Subunit Influenza Vaccines After Each Vaccination for All Seasons</title>
          <population>Adequate data was not available to conduct this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Indirect Protective Effect of Fluad (NH Composition 2007/2008), Compared to Non-flu Control and Flu Control, in Connection to Household-contact Persons Via a Questioning of the Parents About ILI of Persons Living in the Same Household as the Study Child</title>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>As per an amendment to the protocol, the Secondary efficacy endpoints were evaluated in enrolled subjects only and the household members were not included in the trial for the evaluation of indirect vaccine efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu-Control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Indirect Protective Effect of Fluad (NH Composition 2007/2008), Compared to Non-flu Control and Flu Control, in Connection to Household-contact Persons Via a Questioning of the Parents About ILI of Persons Living in the Same Household as the Study Child</title>
          <population>As per an amendment to the protocol, the Secondary efficacy endpoints were evaluated in enrolled subjects only and the household members were not included in the trial for the evaluation of indirect vaccine efficacy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of the 2009-2010 H1N1 Swine Pandemic Caused by a Novel Influenza A (H1N1) Virus of Swine Origin in Unprimed Children Aged 6 to &lt;36 and 6 to &lt;72 Months</title>
        <time_frame>3 weeks after 2nd vaccination</time_frame>
        <population>Adequate data was not available for assessing the incidence rates of the 2009-2010 swine pandemic caused by a novel influenza A (H1N1) virus of swine origin.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV-adj</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Non-flu Control</title>
            <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
          </group>
          <group group_id="O3">
            <title>Flu-Control</title>
            <description>Subjects aged 6 to &lt; 36 months received 0.25 mL and those aged 36 to &lt;72 months received 0.5 mL of each injection of</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of the 2009-2010 H1N1 Swine Pandemic Caused by a Novel Influenza A (H1N1) Virus of Swine Origin in Unprimed Children Aged 6 to &lt;36 and 6 to &lt;72 Months</title>
          <population>Adequate data was not available for assessing the incidence rates of the 2009-2010 swine pandemic caused by a novel influenza A (H1N1) virus of swine origin.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years (3 consecutive influenza seasons: 2007/08, 2008/09 and 2009/10).</time_frame>
      <desc>15 subjects were excluded from safety analysis either because the subjects did not receive any of the study vaccines or the subjects received wrong vaccine at one of the visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>TIV-adj_0.25</title>
          <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
        </group>
        <group group_id="E2">
          <title>TIV-adj_0.5</title>
          <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of adjuvanted trivalent inactivated subunit influenza vaccine</description>
        </group>
        <group group_id="E3">
          <title>Flu-control_0.25</title>
          <description>Subjects aged 6 to &lt; 36 months received 0.25 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
        </group>
        <group group_id="E4">
          <title>Flu-control_0.5</title>
          <description>Subjects aged 36 to &lt; 72 months received 0.5 mL of each injection of non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine</description>
        </group>
        <group group_id="E5">
          <title>Non-Flu-control (TBE/Men C Vaccine)</title>
          <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
        </group>
        <group group_id="E6">
          <title>Non-Flu-control (TBE Vaccine)</title>
          <description>Subjects aged 6 to &lt;12 months received 2 doses of 0.5 mL of Novartis Meningococcal C conjugate vaccine and subjects aged 12 to &lt;72 months received 2 doses of 0.25 mL of TBE vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Arthropod infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hand-foot and mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pseudocroup</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Lice infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Perineal Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Vaccination failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Exposure via ingestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Paracentesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acetonaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Feeding disorder of Infancy or Early childhood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Acquired epileptic aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit / Hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Dysphemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tonsillar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Adenoidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Brain tumour operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1101" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="769" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="989" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="686" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="567" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="375" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="309" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="260" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="147" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="102" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="224" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="122" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="423" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="321" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="325" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="268" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="240" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="128" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="152" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="154" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="79" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="334" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="478" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="250" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="360" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="173" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="179" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="482" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="299" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="412" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="183" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="221" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="125" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="373" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="325" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="163" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="95" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="89" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="226" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="110" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="130" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="62" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="97" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="123" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="362" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="306" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="156" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="174" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="85" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="66" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="66" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="315" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="186" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="263" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="161" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="210" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="166" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="119" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="97" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 17.1">Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1177"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="835"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1069"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="777"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

